The genetic architecture of pneumonia susceptibility implicates mucin biology and a relationship with psychiatric illness

William R. Reay, Michael P. Geaghan, Michelle Agee, Babak Alipanahi, Robert K. Bell, Katarzyna Bryc, Sarah L. Elson, Pierre Fontanillas, Nicholas A. Furlotte, Barry Hicks, David A. Hinds, Karen E. Huber, Ethan M. Jewett, Yunxuan Jiang, Aaron Kleinman, Keng‐Han Lin, Nadia K. Litterman, Jey C. McCreight, Matthew H. McIntyre, Kimberly F. McManus, Joanna L. Mountain, Elizabeth S. Noblin, Carrie A. M. Northover, Steven J. Pitts, G. David Poznik, J. Fah Sathirapongsasuti, Janie F. Shelton, Suyash Shringarpure, Chao Tian, Joyce Y. Tung, Vladimir Vacic, Xin Wang, Catherine H. Wilson, Murray J. CairnsNature Communications 2022 · DOI

TL;DR

This study leverages a massive genome-wide meta-analysis of pneumonia susceptibility (N=391,044) to uncover novel genetic risk factors beyond the well-known MHC region, highlighting the roles of mucin biology (MUC5AC) and immune signaling (TNFRSF1A). Crucially, it reveals a significant genetic overlap between pneumonia and psychiatric conditions, suggesting shared biological pathways and opening avenues for precision medicine and drug repurposing.

What Problem Does This Paper Address?

Pneumonia remains a leading global cause of death, yet our understanding of the host genetic factors that influence susceptibility is incomplete. While some genetic associations have been identified, particularly within the complex Major Histocompatibility Complex (MHC) region, a comprehensive picture of the genetic architecture is lacking. This gap hinders the development of targeted preventative strategies and novel therapeutic interventions. Furthermore, the potential for shared genetic underpinnings between pneumonia and other complex diseases, such as psychiatric disorders, has not been fully explored, limiting opportunities for cross-disease insights and drug repurposing.

Methods

The researchers employed a genome-wide meta-analysis combining self-reported pneumonia diagnoses from 23andMe with clinically ascertained pneumonia data from the FinnGen consortium, resulting in a large effective sample size. Key techniques included:

  • Genome-wide Association Study (GWAS) Meta-analysis: Combining data from two large cohorts to increase statistical power for identifying genetic variants associated with pneumonia susceptibility.
  • Integrative Gene Prioritization: A multi-faceted approach to identify plausible causal genes at identified loci, integrating evidence from eQTLs (expression quantitative trait loci), pQTLs (protein quantitative trait loci), probabilistic fine-mapping (using Approximate Bayes' Factors and FOCUS), gene-based association testing (MAGMA), and in silico functional prediction (CADD, RegulomeDB).
  • Phenome-Wide Association Study (PheWAS): Testing the association of identified genetic variants with a broad range of phenotypes to understand their pleiotropic effects.
  • Genetic Correlation Analysis (LDSR): Estimating the extent to which genetic variants associated with pneumonia are also associated with other traits, particularly psychiatric phenotypes.
  • Latent Causal Variable (LCV) Modeling: Investigating the directionality of genetic relationships between pneumonia and other traits, distinguishing between correlation and partial genetic causality.
  • Mendelian Randomization (MR): Using genetic variants as instrumental variables to infer causal relationships between biochemical markers (CRP, GGT) and pneumonia susceptibility.
  • Pharmagenic Enrichment Score (PES): Developing polygenic risk scores within specific biological pathways to identify potential drug repurposing candidates for precision treatment.

Datasets

  • 23andMe Cohort: Self-reported lifetime pneumonia diagnosis data.
  • FinnGen Consortium (Release 6): Clinically ascertained pneumonia diagnoses.
  • UK Biobank (UKBB): Used for replication studies and for deriving more conservative estimates of population prevalence. Also used for phenome-wide association studies and for testing the PES approach.
  • Psychiatric Genomics Consortium (PGC): GWAS summary statistics for various psychiatric phenotypes.
  • IEUGWAS Database: Used for phenome-wide association studies.
  • 1000 Genomes Project: Reference panel for LD estimation.

Key Insights and Ideas

  • Beyond the MHC: The study successfully identified significant genetic associations for pneumonia susceptibility outside the complex MHC region, pointing to novel biological pathways.
  • Mucin Biology's Role: The strong association with the MUC5AC gene, which encodes a key mucin protein, highlights the importance of airway barrier function and mucus production in pneumonia susceptibility.
  • Immune Signaling Connection: The identification of TNFRSF1A (Tumor Necrosis Factor Receptor Superfamily, Member 1A) suggests a role for inflammatory signaling pathways in pneumonia risk.
  • Pneumonia and Psychiatric Illness Link: A robust genetic correlation was found between pneumonia susceptibility and several psychiatric phenotypes (e.g., MDD, PTSD, ADHD), suggesting shared genetic underpinnings and potentially common biological mechanisms. This is a significant finding with implications for understanding both conditions.
  • Therapeutic Targets Identified: The integrative gene prioritization identified MUC5AC, TNFRSF1A, and IL6R as promising therapeutic targets, with evidence suggesting that inhibiting MUC5AC and TNFRSF1A, and potentially upregulating IL6R, could be beneficial.
  • Precision Medicine Potential: The development of a Pharmagenic Enrichment Score (PES) approach demonstrates how genetic risk profiles within specific pathways can be used to identify individuals who might benefit from targeted therapies or drug repurposing.

Key Results

  • Four novel association signals outside the MHC region were identified for pneumonia susceptibility.
  • The lead SNP for one locus on chromosome 11 was upstream of the MUC5AC gene, and this SNP was also associated with respiratory phenotypes like asthma.
  • The TNFRSF1A gene was a strong candidate for a locus on chromosome 12.
  • A genome-wide meta-analysis of self-reported and clinically ascertained pneumonia showed a high genetic correlation (rg = 0.71).
  • SNP-based heritability (h²SNP) for pneumonia susceptibility was estimated at approximately 2.69% on the liability scale.
  • Significant genetic correlations were observed between pneumonia susceptibility and numerous psychiatric phenotypes, including major depressive disorder (MDD), post-traumatic stress disorder (PTSD), and attention-deficit/hyperactivity disorder (ADHD). These correlations remained significant even after accounting for smoking behavior.
  • Partial genetic causality was suggested between pneumonia and traits like gallbladder disease, elevated GGT, and a self-reported feeling that life was not worth living.
  • Mendelian randomization provided evidence for a causal effect of C-reactive protein (CRP) on pneumonia susceptibility, with each standard deviation increase in CRP associated with an 8% increase in pneumonia odds.
  • The PES approach identified 13 candidate druggable pathways, with "metabolism of proteins" and "post-translational protein modification" showing enrichment for pneumonia genetic risk and overlapping with prioritized genes.

Limitations and Future Work

  • European Ancestry: The study primarily used European ancestry data, limiting generalizability. Future work should focus on trans-ancestral data to better understand global genetic influences.
  • Pneumonia Phenotype Heterogeneity: The study acknowledges that the definition of pneumonia can be challenging and may contribute to the relatively low heritability observed. Further refinement of phenotype definitions and stratified analyses (e.g., by age) are suggested.
  • MHC Region Complexity: The MHC region's immense complexity makes detailed interpretation difficult. Further investigation into specific HLA types is warranted.
  • Causal Inference Nuances: While LCV and MR models provide evidence for causality, they have limitations. The authors emphasize that GCP estimates should not be interpreted as magnitudes of causal effect.
  • Drug Development Validation: The identified therapeutic targets and PES pathways require further clinical validation through trials to confirm their efficacy and safety.
  • Inter-individual Heterogeneity: The authors note that inter-individual genetic heterogeneity might confound the effectiveness of drugs. Future work should explore how to tailor treatments based on individual genetic risk profiles.
  • Rare Variant Interpretation: The interpretation of rare variants, particularly in the MHC region, remains challenging and requires further investigation.

Summary updated

Abstract

Pneumonia remains one of the leading causes of death worldwide. In this study, we use genome-wide meta-analysis of lifetime pneumonia diagnosis (N = 391,044) to identify four association signals outside of the previously implicated major histocompatibility complex region. Integrative analyses and finemapping of these signals support clinically tractable targets, including the mucin MUC5AC and tumour necrosis factor receptor superfamily member TNFRSF1A. Moreover, we demonstrate widespread evidence of genetic overlap with pneumonia susceptibility across the human phenome, including particularly significant correlations with psychiatric phenotypes that remain significant after testing differing phenotype definitions for pneumonia or genetically conditioning on smoking behaviour. Finally, we show how polygenic risk could be utilised for precision treatment formulation or drug repurposing through pneumonia risk scores constructed using variants mapped to pathways with known drug targets. In summary, we provide insights into the genetic architecture of pneumonia susceptibility and genetics informed targets for drug development or repositioning.
BibTeX
@inproceedings{reay2022genetic,
  author = {William R. Reay and Michael P. Geaghan and Michelle Agee and Babak Alipanahi and Robert K. Bell and Katarzyna Bryc and Sarah L. Elson and Pierre Fontanillas and Nicholas A. Furlotte and Barry Hicks and David A. Hinds and Karen E. Huber and Ethan M. Jewett and Yunxuan Jiang and Aaron Kleinman and Keng‐Han Lin and Nadia K. Litterman and Jey C. McCreight and Matthew H. McIntyre and Kimberly F. McManus and Joanna L. Mountain and Elizabeth S. Noblin and Carrie A. M. Northover and Steven J. Pitts and G. David Poznik and J. Fah Sathirapongsasuti and Janie F. Shelton and Suyash Shringarpure and Chao Tian and Joyce Y. Tung and Vladimir Vacic and Xin Wang and Catherine H. Wilson and Murray J. Cairns},
  title = {{The genetic architecture of pneumonia susceptibility implicates mucin biology and a relationship with psychiatric illness}},
  booktitle = {Nature Communications},
  year = {2022},
  doi = {10.1038/s41467-022-31473-3},
}
Figure